The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correction to Vivas et al., N Engl J Med 354(23):2514-2515 June 8, 2006.

Correction
PreviousPrevious
Volume 355:856 August 24, 2006 Number 8

Alemtuzumab for Refractory Celiac Disease in a Patient at Risk for Enteropathy-Associated T-Cell Lymphoma

 

This Article
- PDF
-PDA Full Text

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Vivas, S.
Alemtuzumab for Refractory Celiac Disease in a Patient at Risk for Enteropathy-Associated T-Cell Lymphoma . On page 2514 of the letter, the sentence that begins three lines from the bottom of the right-hand column should have read, "Alemtuzumab was administered according to the conventional therapeutic schedule used in cases of chronic lymphocytic leukemia that is resistant to alkylating agents (30 mg three times per week for 12 consecutive weeks)," not "(30 mg two times per week for 12 consecutive weeks)," as printed.



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.